AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of April 27, 2026, AVTX stock price climbed to $14.42 with 639,627 million shares trading.

AVTX has a beta of 0.76, meaning it tends to be less sensitive to market movements. AVTX has a correlation of 0.02 to the broad based SPY ETF.

AVTX has a market cap of $328.61 million. This is considered a Small Cap stock.

In the last 3 years, AVTX traded as high as $1,130.31 and as low as $3.39.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, VXF, ITOT, IWC, MEDI.

AVTX has outperformed the market in the last year with a price return of +195.5% while the SPY ETF gained +32.2%. However, in the short term, AVTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.4% vs +4.0% return in SPY. But in the last 2 weeks, AVTX shares have fared better than the market returning +5.6% compared to SPY +5.3%.

AVTX support price is $13.06 and resistance is $14.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.